Clinical trial
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
NCT00051675 · XOMA (US) LLC, Industry · Completed
Key facts
| NCT number | NCT00051675 |
|---|---|
| Title | Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas |
| Official title | An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas |
| Lead sponsor | XOMA (US) LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adenocarcinoma |
| Intervention type | Drug |
| Interventions | ING-1(heMAb) |
| Enrollment | 30 |
| Start date | Jul 1, 2002 |
| Completion | Sep 1, 2003 |
| First posted | Jan 16, 2003 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: